Esta web utiliza cookies técnicas, de personalización y análisis, propias y de terceros,
para facilitarle la navegación y analizar estadísticas del uso de la web.
Si continúa navegando, consideramos que acepta su uso
5% de descuentoen todos los libros solicitados por la web
In this book we provide insights into liver cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials.
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical inflammation-induced cancer.
Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
Table of contents (9 chapters) Vaccine Approaches in Hepatocellular Carcinoma
Tagliamonte, Maria (et al.)
Pages 1-17 Natural Killer Cells in Hepatocellular Carcinoma: Anti-Tumor Effect and Therapeutic Potential
Cariani, Elisabetta (et al.)
Pages 19-38 Antigen-Specific T Cell Responses in Hepatocellular Carcinoma
Mizukoshi, Eishiro (et al.)
Pages 39-50 Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma
Iñarrairaegui, Mercedes (et al.)
Pages 51-68 Cytokine-Induced Killer Cells for the Adjuvant Treatment of Patients with HCC
Lee, Jeong-Hoon (et al.)
Pages 69-84 Anti-VEGFR Therapy as a Partner for Immune-Based Therapy Approaches in HCC
Shigeta, Kohei (et al.)
Pages 85-101 Glypican-3 as a Target for Immune Based Therapy in Hepatocellular Carcinoma
Zhang, Yi-Fan (et al.)
Pages 103-119 Immune Suppressor Mechanisms in HCC
Greten, Tim F. (et al.)
Pages 121-135 Impact of Cytokines in Hepatocellular Carcinoma Initiation and Progression